Practically everyone involved in protocol authoring experiences the challenges with the collaborative nature of protocol design and authoring. Authoring teams need to incorporate many perspectives and areas of expertise into each protocol – requiring the ability to facilitate timely decisions and accountability for deadlines. Teams can also benefit from access to standard protocol templates and the ability to iterate with complete traceability.
In this webinar, industry experts will discuss the challenges encountered by protocol authoring teams and present concrete approaches and strategies to minimize these challenges to improve the authoring process.
- Understand the challenges inherent in clinical trial protocol authoring today
- Increase understanding of the current approaches to alleviate challenges in protocol authoring
- Provide insight into best practices for improving the protocol authoring process
PharmD, Deputy Chief Health Officer
IBM Watson Health
Rob DiCicco is currently the Deputy Chief Health Officer at IBM Watson Health. Rob previously served as Vice President of the Clinical Innovation and Digital Platforms Group at GlaxoSmithKline. He was also the Work Stream Leader for the Common Protocol Template Project sponsored by TransCelerate BioPharma and one of the Team Leaders for CTTI's Novel Endpoints Work Stream as part of the mHealth in Clinical Trials Initiative. Rob has more than 25 years of experience in clinical development in a variety of leadership positions in CRO, mid-sized and large pharmaceutical companies. He received his Doctorate of Pharmacy degree at the University of the Sciences of Philadelphia. Over the course of his career he has had a key role in the development of a number of successful new medicines. Rob’s area of expertise includes clinical pharmacology and experimental medicine, innovative clinical trial design, project management and ethics in human research.
Richard (Reb) Buckley, JD, MBA
Strategic Initiatives Lead
Reb Buckley is currently working in the Strategic Initiatives group at Pfizer. Reb was previously in the Clinical Innovation group and has been serving as the Program Lead for Pfizer in the TransCelerate Biopharmaceutical collaboration. In the TransCelerate collaboration, Reb works across the initiatives to ensure that Pfizer has representation for development, and is prepared for any implementation as it becomes required. Reb has over 23 years of experience in the Pharmaceutical industry, working at various Pharmaceutical companies and CROs. Reb Received his JD from Quinnipiac University School of Law and his MBA from the University of Rhode Island. Reb’s area of expertise is in exploring and implementing technical solutions to enhance the clinical trial process for sponsors, investigators and patients.
Cost: No cost!